Feldan Therapeutics partners with TransBIOTech on NSERC-funded project
Feldan Therapeutics is partnering with TransBIOTech on a project funded to the tune of $450,000 by the NSERC to accelerate the development of innovative intralesional treatments. This non-dilutive funding will support Feldan's development of new therapeutic approaches targeting tumor lesions through intralesional injections over a three-year period. TransBIOTech will conduct the in vivo experiments necessary to advance this work.
Evaluate and demonstrate the effectiveness of probiotics
The evaluation of probiotic efficacy cannot be reduced to a single test or isolated model. An integrated approach, combining relevant in vitro and in vivo trials, not only provides a better understanding of the specific mechanisms of action of strains, but also allows the most promising candidates to be selected early on in the development process.
Biena and TransBIOTech receive $300,000 grant
This collaboration aims to advance population health, reduce healthcare costs, and strengthen Canada's leadership in microbiome-based innovation.
